MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay
Year: 2026
Type: article
Source: Blood
Authors: Jan-Michel Heger, Julia Mattlener, Helen Kaul, Justin Ferdinandus, Jessica Schneider, Julia K. Schleifenbaum, Gundolf Schneider, Valdete Schaub, Mathias Hänel, Johannes C. Hellmuth, Judith Dierlamm, Sonja Martin, Stephan Mathas, Julia Meissner, D. Michiel Pegtel, Josée M. Zijlstra, Anna Ossowski, Kerstin Becker, Michael Hallek, Bastian von Tresckow, Peter Borchmann, Sven Borchmann
Institutions: University of Cologne, University Hospital Cologne, University of Tübingen, Klinikum Chemnitz, LMU Klinikum, Ludwig-Maximilians-Universität München, University Medical Center Hamburg-Eppendorf, Robert Bosch Hospital, Max Delbrück Center, Humboldt-Universität zu Berlin, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Charité - Universitätsmedizin Berlin, Heidelberg University, University Hospital Heidelberg, Amsterdam University Medical Centers, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Hovon, Essen University Hospital, University of Duisburg-Essen
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7128451786